PDF(Pubmed)
Abstract：
BACKGROUND: Probiotic supplementation in preterm neonates is standard practice in many centres across the globe. The impact of probiotic supplementation in the neonatal age group on the risk of hospitalisation in infancy has not been reported previously.
METHODS: Infants born < 32 + 6 weeks of gestation in Western Australia were eligible for inclusion. We conducted a retrospective cohort study comparing data from before probiotic supplementation (Epoch 1: 1 December 2008-30 November 2010, n = 1238) versus after (Epoch 2: 1 June 2012-30 May 2014, n = 1422) on the risks of respiratory- and gastrointestinal infection-related hospitalisation. A subgroup analysis of infants born < 28 weeks of gestation was analysed separately for similar outcomes.
RESULTS: Compared to Epoch 1, an 8% reduction in incidence of hospitalisation up to 2 years after birth was observed in Epoch 2 (adjusted incidence rate ratio (IRR) of 0.92; 95% confidence interval (CI); 0.87-0.98), adjusted for gestational age, smoking, socioeconomic status, and maternal age. The rate of hospitalisation for infants born < 28 weeks of gestation was comparable in epochs 1 and 2.
CONCLUSIONS: Infants exposed to probiotic supplementation in the neonatal period experience a reduced risk of hospitalisation in the first two years after discharge from the neonatal unit.
METHODS: Infants born < 32 + 6 weeks of gestation in Western Australia were eligible for inclusion. We conducted a retrospective cohort study comparing data from before probiotic supplementation (Epoch 1: 1 December 2008-30 November 2010, n = 1238) versus after (Epoch 2: 1 June 2012-30 May 2014, n = 1422) on the risks of respiratory- and gastrointestinal infection-related hospitalisation. A subgroup analysis of infants born < 28 weeks of gestation was analysed separately for similar outcomes.
RESULTS: Compared to Epoch 1, an 8% reduction in incidence of hospitalisation up to 2 years after birth was observed in Epoch 2 (adjusted incidence rate ratio (IRR) of 0.92; 95% confidence interval (CI); 0.87-0.98), adjusted for gestational age, smoking, socioeconomic status, and maternal age. The rate of hospitalisation for infants born < 28 weeks of gestation was comparable in epochs 1 and 2.
CONCLUSIONS: Infants exposed to probiotic supplementation in the neonatal period experience a reduced risk of hospitalisation in the first two years after discharge from the neonatal unit.
摘要：
背景：早产儿补充益生菌是全球许多中心的标准做法。以前没有报道过在新生儿年龄组中补充益生菌对婴儿期住院风险的影响。
方法：西澳大利亚州妊娠<32+6周出生的婴儿符合纳入条件。我们进行了一项回顾性队列研究，比较了益生菌补充前（2008年12月1日-2010年11月30日，n=1238）和后（2012年6月2日-2014年5月30日，n=1422）的呼吸和胃肠道感染相关住院风险数据。对出生<28孕周的婴儿进行亚组分析，对相似的结局进行了单独分析。
结果：与时代1相比，在时代2中观察到出生后2年的住院发生率降低了8％（调整后的发生率比率（IRR）为0.92；95％置信区间（CI）；0.87-0.98），调整胎龄，吸烟,社会经济地位,和产妇年龄。在第1期和第2期，妊娠<28周出生的婴儿的住院率相当。
结论：在新生儿期暴露于益生菌补充剂的婴儿在从新生儿病房出院后的头两年内住院的风险降低。
方法：西澳大利亚州妊娠<32+6周出生的婴儿符合纳入条件。我们进行了一项回顾性队列研究，比较了益生菌补充前（2008年12月1日-2010年11月30日，n=1238）和后（2012年6月2日-2014年5月30日，n=1422）的呼吸和胃肠道感染相关住院风险数据。对出生<28孕周的婴儿进行亚组分析，对相似的结局进行了单独分析。
结果：与时代1相比，在时代2中观察到出生后2年的住院发生率降低了8％（调整后的发生率比率（IRR）为0.92；95％置信区间（CI）；0.87-0.98），调整胎龄，吸烟,社会经济地位,和产妇年龄。在第1期和第2期，妊娠<28周出生的婴儿的住院率相当。
结论：在新生儿期暴露于益生菌补充剂的婴儿在从新生儿病房出院后的头两年内住院的风险降低。
